Benzamide, 3,4-dimethoxy-N-propyl- | 349107-90-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzamide, 3,4-dimethoxy-N-propyl-
• 英文别名: 3,4-dimethoxy-N-propylbenzamide
• CAS: 349107-90-0
• 化学式: C₁₂H₁₇NO₃
• mdl: MFCD01215778
• 分子量: 223.272
• InChiKey: IXLDZEGNMDSKHS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Benzamide, 3,4-dimethoxy-N-propyl- 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 生成 N-n-propyl 3,4-dihydroxybenzamide
  参考文献：
  名称：

  Synthesis and in Vitro Evaluation of Two Progressive Series of Bifunctional Polyhydroxybenzamide Catechol-O-methyltransferase Inhibitors

  摘要：

  Two progressive series of molecules with two polyhydroxybenzamide substructures were synthesized and tested as potential inhibitors of catechol-O-methyltransferase (COMT). These compounds were designed for the purpose of enhanced enzyme binding with duplicated substructures separated by a linker section of various lengths. Our results show that potency and mode of inhibition observed with the ''bifunctional'' compounds were a reflection of their bifunctional nature. Furthermore, potency and mode of inhibition were dependent on the length of the linker section. Of the assayed compounds, the optimum linker was found to be diaminopropane. For example, N,N'-1,3-propanediylbis(3,4-dihydroxybenzamide) and N,N'-1,3-propanediylbis(3,4,5-trihydroxybenzamide) demonstrated strong inhibitory action against COMT, with apparent K-i values of 0.3 and 6.0 mu M, respectively.

  DOI：

  10.1021/jm9605187
• 作为产物：
  描述：

  藜芦酸 在 五氯化磷 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 Benzamide, 3,4-dimethoxy-N-propyl-
  参考文献：
  名称：

  Synthesis and in Vitro Evaluation of Two Progressive Series of Bifunctional Polyhydroxybenzamide Catechol-O-methyltransferase Inhibitors

  摘要：

  Two progressive series of molecules with two polyhydroxybenzamide substructures were synthesized and tested as potential inhibitors of catechol-O-methyltransferase (COMT). These compounds were designed for the purpose of enhanced enzyme binding with duplicated substructures separated by a linker section of various lengths. Our results show that potency and mode of inhibition observed with the ''bifunctional'' compounds were a reflection of their bifunctional nature. Furthermore, potency and mode of inhibition were dependent on the length of the linker section. Of the assayed compounds, the optimum linker was found to be diaminopropane. For example, N,N'-1,3-propanediylbis(3,4-dihydroxybenzamide) and N,N'-1,3-propanediylbis(3,4,5-trihydroxybenzamide) demonstrated strong inhibitory action against COMT, with apparent K-i values of 0.3 and 6.0 mu M, respectively.

  DOI：

  10.1021/jm9605187

文献信息

• [EN] POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS<br/>[FR] ANTAGONISTES DE TLR7/8 POLYCYLIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES IMMUNES
  申请人：MERCK PATENT GMBH

  公开号：WO2017106607A1

  公开（公告）日：2017-06-22

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as toll-like receptor 7/8 (TLR7/8) antagonists. In Formula (I), Ring A is aryl or heteroaryl; Ring B is aryl or heteroary; and X is C(R4)2, O, NR4, S, S(R4), or S(R4)2.

  本发明涉及式(I)的化合物及其药学上可接受的组合物，作为Toll样受体7/8（TLR7/8）拮抗剂。在式(I)中，环A是芳基或杂芳基；环B是芳基或杂芳基；X是C(R4)2、O、NR4、S、S(R4)或S(R4)2。
• Total synthesis of aristolactam alkaloids via synergistic C–H bond activation and dehydro-Diels–Alder reactions
  作者：Mallu Chenna Reddy、Masilamani Jeganmohan

  DOI：10.1039/c7sc00161d

  日期：——

  concise total synthesis of aristolactam alkaloids by a synergistic combination of C–H bond activation and dehydro-Diels–Alder reactions is described. To achieve the synthesis two new synthetic methodologies, namely the oxidative cyclization of benzamides with vinyl sulfone leading to 3-methyleneisoindolin-1-ones via a ruthenium-catalyzed C–H bond activation, and a dehydro-Diels–Alder reaction followed by

  描述了通过 C-H 键活化和脱氢-Diels-Alder 反应的协同组合来简明地全合成马兜铃内酰胺生物碱。为了实现合成，采用了两种新的合成方法，即苯甲酰胺与乙烯基砜的氧化环化，通过钌催化的 C-H 键活化生成 3-亚甲基异吲哚啉-1-酮，以及脱氢-狄尔斯-阿尔德反应，然后生成氟化物开发了 3-亚甲基异吲哚啉-1-酮与苯炔的离子介导脱磺酰化。所提出的方法允许从容易获得的起始材料构建所有马兜铃内酰胺环。
• Hansch analysis of veratric acid derivatives as antimicrobial agents
  作者：Balasubramanian Narasimhan、Sucheta Ohlan、Ruchita Ohlan、Vikramjeet Judge、Rakesh Narang

  DOI：10.1016/j.ejmech.2008.05.008

  日期：2009.2

  The synthesis, characterization and antimicrobial evaluation of a new series of veratric acid derivatives are presented. Preliminary in vitro antimicrobial activity of the title compounds was assessed against a panel of microorganisms including Gram-positive and Gram-negative bacteria and fungi. Some of the veratric acid derivatives exhibited significant in vitro antimicrobial activity. QSAR investigation

  介绍了一系列新的veratric acid衍生物的合成，表征和抗菌性评估。评估标题化合物对包括革兰氏阳性和革兰氏阴性细菌和真菌在内的一系列微生物的初步体外抗菌活性。一些维甲酸衍生物表现出显着的体外抗菌活性。通过QSAR研究发现了维甲酸衍生物的不同理化参数与其抗菌活性之间的相关性，表明拓扑参数在描述抗菌活性方面的重要性。
• QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS
  申请人：Collingwood Stephen Paul

  公开号：US20100041887A1

  公开（公告）日：2010-02-18

  Compounds of formula I in salt or zwitterionic form wherein, wherein R 1 , R 2 , R 3 , and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  具有式I的化合物，其以盐或双离子形式存在，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由肌肉乙酰胆碱M3受体介导的疾病。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。
• Quinuclidine derivatives binding to mucarinic m3 receptors
  申请人：Collingwood Paul Stephen

  公开号：US20070060563A1

  公开（公告）日：2007-03-15

  Compounds of formula I in salt or zwitterionic form wherein, wherein R 1 , R 2 , R 3 , and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  具有式I的盐或双电离形式的化合物，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由肌肉型M3受体介导的病症。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。